Myeloperoxidase (MPO) – possible diagnosis biomarker and risk stratification in myocardial inotropism deficit induced by chronic ischemic heart disease

The myeloperoxidase levels of 208 patients with ischemic heart disease hospitalized for congestive heart failure were tested at admission, and discharge after 14 days. The calculations for the serum average concentration/lot/date, were made, subsequent, using the values of the tested parameters regarding MPO (admission and discharge) the mean concentration/lot was made, regardless of time of determination. The calculated average values analyses of the three MPO serum parameters were constantly elevated and permanently matched the myocardial contractility deficiency class. The integrated data of the study, allows us to propose the MPO’s circulating concentration as a diagnosis and risk assessment biomarker in the etiology of myocardial ischemia for chronic cardiac failure

THE IMPORTANCE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND TREATMENT OF MUSCULOSKELETAL PROBLEMS OF HAEMOPHILIA A

Haemophilia A, defined by a deficiency of clotting factor VIII, can cause bleeding in various locations, especially on muscles and joints. For these patients, ultrasonography plays a very important role in the monitoring and shaping of the replacement treatment with factor VIII, by confirming the time when full clinical-imaging complete remission is obtained